Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
1.
West Indian med. j ; 67(2): 98-104, Apr.-June 2018. tab, graf
Artículo en Inglés | LILACS | ID: biblio-1045825

RESUMEN

ABSTRACT Objective: To explore the application methods of mitogen-activated protein kinase signal pathway inhibitors SP600125 and SB203580 in long-term in vivo experiments. Methods: A total of 55 healthy New Zealand rabbits were randomly divided into blank control group, model control group, SP low dose group, SP high dose group, SP blank group, SB low dose group, SB high dose group, SB blank group, dimethyl sulfoxide (DMSO) control group, DMSO blank group, and positive control group. Since the first day of the experiment, each group was administered the corresponding treatment for four weeks continuously. Then, the myocardial c-Jun N-terminal kinase (JNK) and the total protein of p38, protein phosphorylation and its gene expression levels were detected. Results: After intravenous treatment with adriamycin, the myocardial phosphorylate-JNK (p-JNK) and phosphorylate-p38 (p-p38) levels in all groups were increased to varying degrees, of which the model control group increased the most significantly (p < 0.05). Compared with the model control group, the myocardial p-JNK and p-p38 increased more slowly in the SP low dose group, SP high dose group, SB low dose group, SB high dose group and positive control group (p < 0.05), of which the increase in the SP high dose group and the SB high dose group was the slowest (p < 0.05). After four weeks, the total protein and messenger ribonucleic acid of the myocardial JNK and p38 in all groups had no statistically significant difference (p > 0.05). Conclusion: The continuous intravenous injection of SP600125 and SB203580 for four weeks significantly reduced the protein phosphorylation levels of JNK and p38, which provides a practical avenue for the long-term study in vivo.


RESUMEN Objetivo: Explorar los métodos de aplicación de los inhibidores SP600125 y SB203580 de la vía de señalización de la proteína quinasa activada por mitógeno en experimentos in vivo a largo plazo. Métodos: Un total de 55 conejos sanos de Nueva Zelandia fueron divididos aleatoriamente en los grupos siguientes: grupo de control en blanco, grupo de control modelo, grupo de dosis baja SP, grupo de dosis alta SP, grupo en blanco SP, grupo de dosis baja SB, grupo de dosis alta SB, grupo en blanco SB, grupo de control dimetilsulfóxido (DMSO), grupo en blanco DMSO, y grupo de control positivo. Desde el primer día del experimento, a cada grupo se le administró el tratamiento correspondiente por cuatro semanas continuas. Entonces, se detectaron la quinasa c-Jun N-terminal (JNK) miocárdica y la proteína p38 total, así como la fosforilación proteica y sus niveles de expresión génica. Resultados: Después del tratamiento intravenoso con adriamicina, los niveles de fosfo-JNK (p-JNK) y fosfo-p38 (p-p38) del miocardio aumentaron en todos los grupos en diversos grados, siendo el aumento del grupo de control modelo el más significativo (p < 0.05). En comparación con el grupo de control modelo, p-JNK y p-p38 miocárdicos aumentaron más lentamente en el grupo de dosis baja SP, el grupo de dosis alta SP, el grupo de dosis baja SB, el grupo de dosis alta SB, y el grupo de control positivo (p < 0.05). De estos, el aumento en el grupo de dosis alta SP y el grupo de dosis alta SB fue el más lento (p < 0.05). Después de cuatro semanas, la proteína total y el ácido ribonucleico mensajero de JNK y p38 miocárdicos en todos los grupos, no tuvieron diferencias significativas (p > 0.05). Conclusión: La inyección intravenosa continua de SP600125 y SB203580 durante cuatro semanas redujo significativamente los niveles de fosforilación proteica de JNK y p38, lo que proporciona una vía práctica para el estudio a largo plazo in vivo.


Asunto(s)
Humanos , Masculino , Conejos , Doxorrubicina/farmacología , Proteínas Quinasas Activadas por Mitógenos/efectos de los fármacos , Inhibidores de Proteínas Quinasas/farmacología , Fosforilación/efectos de los fármacos , Factores de Tiempo , Transducción de Señal/efectos de los fármacos , Distribución Aleatoria , Expresión Génica
2.
Braz. j. med. biol. res ; 49(6): e5227, 2016. tab
Artículo en Inglés | LILACS | ID: lil-781417

RESUMEN

This study reports a case of a gonadotropin-releasing hormone agonist trigger in a young female with myelodysplastic syndrome (MDS) who underwent fertility preservation using random-start controlled ovarian stimulation. This method involves the stimulation of the ovary regardless of a patient's menstrual-cycle phase. A review of the related literature is also provided. A 17-year-old patient was diagnosed with MDS and required initiation of peripheral blood stem cell transplantation within a maximum of 3 weeks and was in the luteal phase of the menstrual cycle when the possibility of attempting preservation of fertility was presented to her. She opted for a random-start controlled ovarian stimulation with gonadotropins. With successful hemorrhagic prophylaxis, 17 oocytes were retrieved including 10 mature and 7 immature oocytes. Of the immature oocytes, 3 were successfully matured in vitro and a vitrification protocol was used to freeze the 13 mature oocytes.


Asunto(s)
Humanos , Femenino , Adolescente , Preservación de la Fertilidad/métodos , Síndromes Mielodisplásicos/fisiopatología , Inducción de la Ovulación/métodos , Criopreservación/métodos , Ciclo Menstrual/fisiología , Recuperación del Oocito/métodos , Oocitos/fisiología , Reproducibilidad de los Resultados , Resultado del Tratamiento
3.
Indian J Cancer ; 2014 Feb; 51(6_Suppl): s37-41
Artículo en Inglés | IMSEAR | ID: sea-156784

RESUMEN

OBJECTIVE: To investigate the feasibility, safety and short term efficacy of video assisted thoracoscopic (VATS) lobectomy for patients with earlystage lung cancer. METHODS: We reviewed clinical data of 138 consecutive patients with early stage lung cancer who underwent lobectomy in the First People’s Hospital of Jining during the January 2010 to May 2012. Of them, 71 cases were performed complete VATS, male 39 cases, female 32 cases, age (57.9 ± 10.6) years old; 67 cases were performed thoracotomy, male 36 cases, female 31 cases, age (60.3 ± 8.2) years old. Clinical features were collected and compared. RESULTS: Operations of two groups were successfully finished. Compared with thoracotomy group, the differences in intraoperative blood loss (147 ± 113 ml vs. 146 ± 91 ml), number of lymph node dissection group (3.1 ± 1.3 vs. 3.4 ± 1.3), the number of lymph node dissection (9.9 ± 3.6 vs. 10.0 ± 3.6), and vision analog score (VAS) of postoperative 1st and 3rd day in VATS group were not statistically significant (P > 0.05). Statistical differences were observed in operation time (119 ± 27 min vs. 135 ± 29 min), the thoracic drainage tube time (3.0 ± 0.9 d vs. 3.8 ± 1.2 d), postoperative hospital stay (8.0 ± 2.1 d vs. 10.2 ± 5.4 d), postoperative VAS of 30th day (2.6 ± 0.7 vs. 3.2 ± 1.1), and postoperative complications (8.5% vs. 19.4%) between the two groups (P < 0.05). CONCLUSION: Video assisted thoracoscopic lobectomy for early lung cancer is safe and effective, with fewer traumas, fewer complications, faster postoperative recovery, milder chronic chest pain, and other advantages. At the same time, the lymph node dissection of VATS lobectomy is similar to that of thoracotomy.


Asunto(s)
Adulto , Anciano , Femenino , Humanos , Neoplasias Pulmonares/cirugía , Escisión del Ganglio Linfático/métodos , Masculino , Neumonectomía/métodos , Cirugía Torácica Asistida por Video/métodos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA